The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
5h
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...
Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the ...
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to ...
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...
Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the ...
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.
The chief executive of the drugmaker Novo Nordisk, Lars Fruergaard Jørgensen, is scheduled to face tough questions Tuesday on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback